Table 2.

Representative studies of adjuvant chemotherapy for stage II and/or stage III CRC.

Author (year)	Regimen	DFS∗∗	P	OS∗∗	P
Moertel (1995) [36]	5-FU/LEV versus none	63% versus 47% (3.5 y)	<0.0001	71% versus 55% (3.5 y)	0.0064
Francini (1994) [37]	5-FU/LV versus none	74% versus 59% (5 y)	0.005	79% versus 65% (5 y)	0.0044
IMPACT (1995) [38]	5-FU/LV versus none	71% versus 62% (3 y)	<0.0001	83% versus 78% (3 y)	0.018
O'Connell (1997) [39]	5-FU/LV versus none	74% versus 58% (5 y)	0.001	74% versus 63% (5 y)	0.01
André (2004) [40]	FL + Oxali versus FL	78% versus 73% (3 y)	0.002	–	–
Kuebler (2007) [41]	FLOX versus FULV	73% versus 67% (4 y)	0.0034	–	–
André (2009) [42]	FOLFOX4 versus LV5FU2	66% versus 59% (5 y)	0.005	73% versus 69% (6 y)	0.023

^∗∗Percentage of survival at indicated years in parentheses. y, years; –, not mentioned in the article.